Title: The association of fecal calprotectin and respiratory exacerbation in cystic fibrosis patients
Version: 2 Date: 14 Jun 2022
Reviewer's report:
Thank you for the opportunity to review your manuscript.Fecal calprotectin (FC) is an important
marker of gastrointestinal inflammation, but has although be attributed to swallowed sputum. It
is difficult to distinguish, but the the reduction of increased sputum is a hallmark of treatment
of pulmonary exacerbation. The well written and discussed study add additional value to the
limited data in the literature .
Was there any difference in FC in the 50% of patients, which had a recurrence after 100 days,
compared to the patients, which did not had a recurrence?
Please add a discussion about limitations  like small patient group.
Please report the pancreatic status - all PI?
Please report on bacterial infection and antibiotic treatment (broad-spectrum or small spectrum
antibiotics?).
The absolute weight and height (Table 1) did not well characterize the patients from a different
age-groups. A weight or height - Z-Score would be more appropriate. The BMI z-Score is
although helpful and is appropriate. What reference did you use to calculate BMI- Z-Score?.
Please report the number of patients  for each age group/female (Table 3).
Please quantify hemoptysis (severe (> 250 ml/day) or mild/scanty (Table 2) ?
The clinical manifestation in Table 2 could be reduced (excluding Clubbing, Osteoporosis,
Pallor, Tooth Decay, respiratory distress). What is covered by other manifestations? Are there
any GI-symptoms ?
Title: The association of fecal calprotectin and respiratory exacerbation in cystic fibrosis patients
Version: 2 Date: 14 Jun 2022
Reviewer's report:
Thank you for the opportunity to review your manuscript.Fecal calprotectin (FC) is an important
marker of gastrointestinal inflammation, but has although be attributed to swallowed sputum. It
is difficult to distinguish, but the the reduction of increased sputum is a hallmark of treatment
of pulmonary exacerbation. The well written and discussed study add additional value to the
limited data in the literature .
Was there any difference in FC in the 50% of patients, which had a recurrence after 100 days,
compared to the patients, which did not had a recurrence?
Please add a discussion about limitations  like small patient group.
Please report the pancreatic status - all PI?
Please report on bacterial infection and antibiotic treatment (broad-spectrum or small spectrum
antibiotics?).
The absolute weight and height (Table 1) did not well characterize the patients from a different
age-groups. A weight or height - Z-Score would be more appropriate. The BMI z-Score is
although helpful and is appropriate. What reference did you use to calculate BMI- Z-Score?.
Please report the number of patients  for each age group/female (Table 3).
Please quantify hemoptysis (severe (> 250 ml/day) or mild/scanty (Table 2) ?
The clinical manifestation in Table 2 could be reduced (excluding Clubbing, Osteoporosis,
Pallor, Tooth Decay, respiratory distress). What is covered by other manifestations? Are there
any GI-symptoms ?
Please review this paper.
user
Title: The association of fecal calprotectin and respiratory exacerbation in cystic fibrosis patients
Version: 2 Date: 14 Jun 2022
Reviewer's report:
Thank you for the opportunity to review your manuscript.Fecal calprotectin (FC) is an important
marker of gastrointestinal inflammation, but has although be attributed to swallowed sputum. It
is difficult to distinguish, but the the reduction of increased sputum is a hallmark of treatment
of pulmonary exacerbation. The well written and discussed study add additional value to the
limited data in the literature .
Was there any difference in FC in the 50% of patients, which had a recurrence after 100 days,
compared to the patients, which did not had a recurrence?
Please add a discussion about limitations  like small patient group.
Please report the pancreatic status - all PI?
Please report on bacterial infection and antibiotic treatment (broad-spectrum or small spectrum
antibiotics?).
The absolute weight and height (Table 1) did not well characterize the patients from a different
age-groups. A weight or height - Z-Score would be more appropriate. The BMI z-Score is
although helpful and is appropriate. What reference did you use to calculate BMI- Z-Score?.
Please report the number of patients  for each age group/female (Table 3).
Please quantify hemoptysis (severe (> 250 ml/day) or mild/scanty (Table 2) ?
The clinical manifestation in Table 2 could be reduced (excluding Clubbing, Osteoporosis,
Pallor, Tooth Decay, respiratory distress). What is covered by other manifestations? Are there
any GI-symptoms ?
assistant